Previous 10 | Next 10 |
- Initial data from ongoing Phase 2a study in geographic atrophy demonstrated ability of GEM103 to durably regulate complement and showed a differentiated safety profile with no increased risk of CNV - Completed enrollment in Phase 2a study of GEM103 in wet AMD with six-month ...
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to par...
Shares of Gemini Therapeutics Inc. (NASDAQ:GMTX) traded at a new 52-week low today of $4.60. This new low was reached on approximately average trading volume as 660,000 shares traded hands, while the average 30-day volume is approximately 760,000 shares. Gemini Therapeutics Inc. (NASDAQ:...
Gemini Therapeutics Inc. (NASDAQ:GMTX) traded at a new 52-week low today of $4.90. Approximately 660,000 shares have changed hands today, as compared to an average 30-day volume of 749,000 shares. Gemini Therapeutics Inc is a clinical-stage precision medicine company developing novel the...
Gemini Therapeutics Inc. (NASDAQ:GMTX) traded today at a new 52-week low of $4.85. This new low was reached on approximately average trading volume as 660,000 shares traded hands, while the average 30-day volume is approximately 749,000 shares. Gemini Therapeutics Inc. (NASDAQ:GMTX) is c...
Gemini Therapeutics Inc. (NASDAQ:GMTX) traded today at a new 52-week low of $5.94. So far today approximately 660,000 shares have been exchanged, as compared to an average 30-day volume of 197,000 shares. Gemini Therapeutics Inc. (NASDAQ:GMTX) is currently priced 89.7% above its average ...
Gemini Therapeutics Inc. (NASDAQ:GMTX) traded at a new 52-week low today of $6.26. Approximately 660,000 shares have changed hands today, as compared to an average 30-day volume of 197,000 shares. Gemini Therapeutics Inc. (NASDAQ:GMTX) defies analysts with a current price ($6.32) 90.2% a...
Shares of Gemini Therapeutics Inc. (NASDAQ:GMTX) traded today at $6.44, breaking its 52-week low. So far today approximately 660,000 shares have been exchanged, as compared to an average 30-day volume of 197,000 shares. Gemini Therapeutics Inc is a clinical-stage precision medicine compa...
JuSun/iStock via Getty Images During the week ended June 25, 2021, Healthcare sector rose 2.01% and Healthcare Select Sector SPDR ETF (XLV) gained 1.58% compared to weekly gain of 2.82% of S&P 500 ETF. Leading the top gainers pack was Atossa Therapeutics (ATO...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. The S&P 500 closed the week at another record high, posting its best weekly performance since February, as investors bet that higher infl...
News, Short Squeeze, Breakout and More Instantly...
Gemini Therapeutics Inc. Company Name:
GMTX Stock Symbol:
NASDAQ Market:
Disc Medicine Receives FDA Orphan Drug Designation for Bitopertin for the Treatment of Erythropoietic Protoporphyria PR Newswire WATERTOWN, Mass. , Dec. 27, 2022 /PRNewswire/ -- Disc Medicine, Inc. ("Disc"), a clinical-stage biopharmaceutical company focused on t...
Disc Medicine Initiates AURORA, a Phase 2 Clinical Study of Bitopertin in Adults with Erythropoietic Protoporphyria (EPP) PR Newswire AURORA study designed to evaluate bitopertin as a potential disease-modifying treatment for adults with EPP in the United States ...